Recent News

• 05.05.2025 - Vertex Pharmaceuticals Q1 2025 Conference Call
• 05.05.2025 - Vertex Pharmaceuticals Q1 2025 Conference Call
• 04.11.2025 - Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis
• 04.11.2025 - Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis
• 04.07.2025 - Vertex to Announce First Quarter 2025 Financial Results on May 5th
• 04.07.2025 - Vertex to Announce First Quarter 2025 Financial Results on May 5th
• 04.07.2025 - European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis
• 04.07.2025 - European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis
• 04.03.2025 - Educated and empowered: Emani’s story with AMKD
• 04.03.2025 - CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Recent Filings

• 04.03.2025 - ARS Annual Report to Security Holders
• 04.03.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.03.2025 - DEF 14A Other definitive proxy statements
• 03.28.2025 - 8-K Current report
• 03.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.13.2025 - 144 Report of proposed sale of securities
• 03.12.2025 - 4 Statement of changes in beneficial ownership of securities